A stem cell and biomaterial strategy to improve stroke recovery
Project Lead
Dr Bradley Broughton, Monash University
Project Team
Dr Mibel Aguilar, Monash University; Dr John Forsythe, Monash University; Dr Helena Parkington, Monash University; Dr Thanh Phan, Monash University; Dr Henry Ma, Monash University; Dr Leon Teo, Monash University
Project Summary
Problem
Current treatments for stroke are limited in their ability to effectively promote brain repair and improve neurological function due to challenges like severe inflammation and poor cell survival of administered stem cells.
Solution
Led by an interdisciplinary team, this project aims to develop AMGEL, a novel hydrogel encapsulating human amnion epithelial cells (hAECs), to enhance their survival and therapeutic efficacy in stroke recovery. By providing a supportive environment for hAECs, AMGEL aims to overcome the limitations of current stem cell therapies, offering a potential breakthrough in stroke treatment.
Impact
Successful development of AMGEL could revolutionise stroke treatment by providing a new, effective therapeutic option that promotes brain repair and improves patient outcomes. The project's focus on enhancing stem cell survival and therapeutic effects not only addresses a critical unmet medical need but also holds significant commercial potential in the healthcare market. Moreover, AMGEL's applicability may extend beyond stroke to other neurological conditions, broadening its impact on healthcare and patient well-being. Consumer and stakeholder engagement ensures that the treatment aligns with patient needs and preferences, enhancing its acceptance and adoption in clinical practice. Through rigorous preclinical studies and collaboration with leading clinicians, the project aims to advance towards clinical trials and eventual market availability, contributing to advancements in stroke care globally